Applied Therapeutics' Rare Disease Drug Fails Another Phase 3 Trial After FDA Rejection on May 19, 2025 Aldose Reductase Inhibitor Apply Cautionary Warning Classical galactosemia clinical trial conduct Govorestat Infrequent rejection United States Food and Drug Administration +